Glaukos (GKOS) Rating Lowered to Hold at Stifel Nicolaus

Stifel Nicolaus downgraded shares of Glaukos (NYSE:GKOS) from a buy rating to a hold rating in a research note published on Friday morning, Marketbeat reports. The brokerage currently has $32.00 target price on the medical instruments supplier’s stock, down from their previous target price of $39.00.

GKOS has been the topic of several other research reports. ValuEngine raised shares of Glaukos from a sell rating to a hold rating in a research note on Wednesday, April 4th. William Blair reaffirmed an outperform rating on shares of Glaukos in a research note on Friday, March 23rd. Cantor Fitzgerald set a $48.00 target price on shares of Glaukos and gave the company a buy rating in a research note on Wednesday, January 10th. Zacks Investment Research lowered shares of Glaukos from a hold rating to a sell rating in a research note on Tuesday, February 13th. Finally, BMO Capital Markets reaffirmed an outperform rating and issued a $36.00 target price (down previously from $38.00) on shares of Glaukos in a research note on Thursday, March 1st. Two analysts have rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the stock. Glaukos has an average rating of Hold and an average price target of $40.38.

How to Become a New Pot Stock Millionaire

Shares of NYSE:GKOS opened at $27.62 on Friday. Glaukos has a 12 month low of $23.08 and a 12 month high of $48.89. The stock has a market cap of $959.54, a price-to-earnings ratio of 184.13 and a beta of 1.05.

Glaukos (NYSE:GKOS) last issued its quarterly earnings data on Wednesday, February 28th. The medical instruments supplier reported $0.03 EPS for the quarter, topping analysts’ consensus estimates of $0.01 by $0.02. Glaukos had a negative net margin of 0.06% and a positive return on equity of 4.03%. The firm had revenue of $41.65 million for the quarter, compared to analyst estimates of $40.83 million. The business’s quarterly revenue was up 25.6% on a year-over-year basis. equities analysts forecast that Glaukos will post -0.38 earnings per share for the current year.

In related news, Director Jonathan Silverstein sold 464,583 shares of Glaukos stock in a transaction that occurred on Friday, March 2nd. The shares were sold at an average price of $32.29, for a total transaction of $15,001,385.07. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Orbimed Advisors Llc sold 836,500 shares of Glaukos stock in a transaction that occurred on Tuesday, March 6th. The stock was sold at an average price of $32.02, for a total transaction of $26,784,730.00. The disclosure for this sale can be found here. 16.40% of the stock is owned by company insiders.

Institutional investors have recently added to or reduced their stakes in the stock. Valeo Financial Advisors LLC bought a new position in Glaukos during the 3rd quarter worth approximately $111,000. First Republic Investment Management Inc. boosted its stake in Glaukos by 47.1% during the 3rd quarter. First Republic Investment Management Inc. now owns 8,300 shares of the medical instruments supplier’s stock worth $274,000 after acquiring an additional 2,659 shares during the last quarter. Meadow Creek Investment Management LLC bought a new position in Glaukos during the 4th quarter worth approximately $336,000. MetLife Investment Advisors LLC bought a new position in Glaukos during the 4th quarter worth approximately $349,000. Finally, Landscape Capital Management L.L.C. acquired a new stake in Glaukos during the 4th quarter worth approximately $362,000.

WARNING: This article was published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States & international copyright legislation. The original version of this article can be read at https://www.chaffeybreeze.com/2018/04/16/glaukos-gkos-rating-lowered-to-hold-at-stifel-nicolaus.html.

About Glaukos

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma.

Analyst Recommendations for Glaukos (NYSE:GKOS)

Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply